Research & Studies
Share your love
From lab to clinic: Advancing ophthalmic technology | Ophthalmology Times
Emerging diagnostic and surgical technologies are enhancing precision, improving efficiency, and shaping the future of patient care in ophthalmology. (Image credit: AdobeStock/Olivier Le Moal) As ophthalmic technology continues to advance, new diagnostic and surgical devices are redefining precision, efficiency, and…
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times
(Image Credit: AdobeStock) The structural differences among newer second-generation anti-VEGF agents—and their implications for clinical efficacy and treatment durability—were the focus of a recent Ophthalmology Times Case-Based Roundtable®. The discussion also highlighted real-world experiences and evidence regarding extended treatment intervals…
What if? Ophthalmology without OCT – Part 3 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Throwback Series: From epidemic to innovation in corneal surgery | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the company’s request for approval of its prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg.1 The FDA cited unresolved…
Cataract and refractive surgery: Trends, challenges, and innovations | Ophthalmology Times
Ongoing innovation in cataract and refractive surgery is driving improved precision, safety, and patient outcomes. (Image credit: AdobeStock/Seventyfour) Cataract and refractive surgery continues to evolve at a rapid pace, driven by advances in intraocular lenses (IOLs), laser technology, and surgical…
Topcon Healthcare seeks to advance company through acquisition and new investment | Ophthalmology Times
Image credit: AdobeStock/Lance Topcon Healthcare will acquire Toku, Inc., according to a press release issued by the company. Toku is a healthcare artificial intelligence (AI) company that uses color fundus photographs to deliver assessments of health. The release notes that…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…